Key points are not available for this paper at this time.
The term "clinically amyopathic dermatomyositis'' was first introduced by Pearson in the 1960s to differentiate individuals exhibiting typical skin features of dermatomyositis but lacking clinical evidence of myositis.Clinically, there are two types of amyopathic dermatomyositis (CADM): amyopathic DM and hypo myopathic DM.Interstitial Lung Disease(ILD) is regarded as a frequent serious consequence, with a 5-65% documented prevalence.Anti-melanoma differentiation-associated gene 5 (MDA-5) is a specific autoantibody that is positive in a fraction of individuals with CADM.Glucocorticoids are the initial treatment choice while immunomodulators can be used in refractory cases.In our case,60-year-old female patient with complaints of cough, breathlessness and fever was MDA-5 positive with multiple hyperpigmented skin lesions over hands ,face and chest, painful oral ulcers, elevated total creatinine phosphokinase(CPK), elevated ESR and positive ANA and Ro-52 and received the treatment with mycophenolate mofetil, prednisolone, dextromethorphan syrup, rituximab, cyclophosphamide, and tacrolimus.
Prajapati et al. (Mon,) studied this question.